Overview

Trabectedin for Recurrent Grade II/III Meningioma

Status:
Completed
Trial end date:
2019-01-16
Target enrollment:
Participant gender:
Summary
The aim of this study is to collect data on activity, toxicity and quality of life of trabectedin therapy in patients with recurrent high-grade meningioma.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Treatments:
Trabectedin